X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through this partnership, BlueSphere will focus on the clinical development of lead product, BSB-1001 for treating patients with relapsed or refractory acute myeloid leukemia.
Lead Product(s): BSB-1001
Therapeutic Area: Oncology Product Name: BSB-1001
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: NMDP BioTherapies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 25, 2024
Details:
The collaboration will seek to advance a novel TCR T-cell therapy, TCX-201, targeting recurrent respiratory papillomatosis (RRP), a rare orphan disease.
Lead Product(s): TCR T-cell Therapy
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 04, 2024
Details:
BSB-1001 is an investigational T cell receptor (TCR) T-cell therapy developed by BlueSphere Bio. It is baing evaluated for the treatment of acute myeloid leukemia (AML).
Lead Product(s): BSB-1001
Therapeutic Area: Oncology Product Name: BSB-1001
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2024
Details:
BSB-1001, targeting the minor HA-1 and part of BlueSphere’s TCX-101 Program, is the first TCR-based clinical candidate generated using TCXpress and is in development for the treatment of AML, ALL and MDS in conjunction with allogeneic hematopoietic stem cell transplantation.
Lead Product(s): BSB-1001
Therapeutic Area: Oncology Product Name: BSB-1001
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
TCX-101 program targets minor histocompatibility antigens by engineering TCR T cells specific to a particular miHA. This allows for achieving graft-vs.-leukemia (GVL) with a lower risk for graft-vs.-host disease (GVHD) in allogeneic hematopoietic stem cell transplant.
Lead Product(s): TCX – 101
Therapeutic Area: Oncology Product Name: TCX – 101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2022
Details:
TCX-101 program targets minor histocompatibility antigens by engineering TCR T cells specific to a particular miHA. This allows for achieving graft-vs.-leukemia (GVL) with a lower risk for graft-vs.-host disease (GVHD) in allogeneic hematopoietic stem cell transplant.
Lead Product(s): TCX – 101
Therapeutic Area: Oncology Product Name: TCX – 101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2022
Details:
TCX-101, is a proprietary high-throughput and efficient T-cell receptor (TCR) capture, expression and functional screening platform capable of processing thousands of single T cells directly into functionally expressed TCRs.
Lead Product(s): TCX-101
Therapeutic Area: Oncology Product Name: TCX-101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2022
Details:
Preclinical data demonstrating the potential of its novel high throughput TCXpress™ platform to efficiently identify TCRs against minor histocompatibility antigens (miHAs) for the future clinical development of adoptive TCR T cell therapy.
Lead Product(s): TCX-101
Therapeutic Area: Oncology Product Name: TCX-101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
TCX-101 program targets minor histocompatibility antigens (miHAs) by engineering TCR T cells specific to a particular miHA. This allows for achieving graft-vs.-leukemia (GVL) with a lower risk for graft-vs.-host disease (GVHD) in allogeneic hematopoietic stem cell transplant.
Lead Product(s): TCX-101
Therapeutic Area: Oncology Product Name: TCX-101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
